Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.

@article{Yong2009PrimitiveQC,
  title={Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.},
  author={Agnes S. M. Yong and Keyvan Keyvanfar and Nancy Fern Hensel and Rhoda Eniafe and Bipin N Savani and Maria L. Berg and Andreas Lundqvist and Sharon Adams and Elaine Marie Sloand and John M. Goldman and Richard Childs and A. J. Barrett},
  journal={Blood},
  year={2009},
  volume={113 4},
  pages={875-82}
}
Primitive quiescent CD34(+) chronic myeloid leukemia (CML) cells are more biologically resistant to tyrosine kinase inhibitors than their cycling counterparts; however, graft-versus-leukemia (GVL) effects after allogeneic stem cell transplantation (SCT) probably eliminate even these quiescent cells in long-term surviving CML transplant recipients. We studied the progeny of CD34(+) cells from CML patients before SCT, which were cultured 4 days in serum-free media with hematopoietic growth… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

cancer cells to death receptor - mediated apoptosis

  • TJ Sayers, AD Brooks, CY Koh
  • 2008

Bortezomib enhances the antitumor activity of adoptively infused natural killer cells in vivo: a novel approach to override KIR-mediated inhibition of NK cell cytotoxicity [abstract

  • A Lundqvist, S Rao, A Smith
  • Blood
  • 2007

Bortezomib has anti-proliferative and apoptotic effects against CML stem cells, including the quiescent population [abstract

  • N Heaney, F Pellicano, L Crawford, S Irvine, TL. Holyoake
  • Blood
  • 2007

Similar Papers

Loading similar papers…